Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08PXM
|
|||
| Former ID |
DIB010882
|
|||
| Drug Name |
MDX-214
|
|||
| Synonyms |
CD89 monoclonal antibody (cancer, autoimmune disease), Medarex
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Discontinued in Phase 1/2 | [1] | |
| Company |
Medarex Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Immunoglobulin alpha Fc receptor (FCAR) | Target Info | . | [2] |
| KEGG Pathway | Phagosome | |||
| Staphylococcus aureus infection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019614) | |||
| REF 2 | A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of MDX-214, a novel immune-mediated mechanism agent targeting the epithelial growth factor receptor (EGFR), in patients with advanced solid tumors. Journal of Clinical Oncology, Vol 24, No 18S (June 20 Supplement), 2006: 2523. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.